E
BBIO icon

Ergoteles’s BridgeBio Pharma BBIO Stock Holding History

Ergoteles’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-21,932
Closed -$167K – 1263
2022
Q4 		$167K Sell
21,932
-9,062
-29% -$86.8K 0.01% 1121
2022
Q3 		$308K Buy
+30,994
New +$322K 0.01% 964
2021
Q4 		– Sell
-106,600
Closed -$5M – 1241
2021
Q3 		$5M Buy
+106,600
New +$5.71M 0.18% 149
2021
Q1 		– Sell
-35,600
Closed -$2.53M – 804
2020
Q4 		$2.53M Buy
35,600
+29,200
+456% +$1.41M 0.08% 228
2020
Q3 		$240K Buy
+6,400
New +$201K 0.03% 411

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return

Ergoteles's BBIO Position: Q1 2023 in Review

Ergoteles sold out of BridgeBio Pharma (BBIO) in Q1 2023, closing a stake of 21,932 shares — an estimated $167K sold.

Ergoteles first reported a position in BBIO in Q3 2020 and held it in 5 quarters. The position peaked at $5M in Q3 2021. 213 funds tracked by Wall St. Rank hold BBIO as of Q1 2023.

  • Ergoteles reported no remaining BridgeBio Pharma position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 21,932 BridgeBio Pharma shares in Q1 2023, an estimated $167K.
  • Ergoteles first reported a position in BridgeBio Pharma in Q3 2020 and held it in 5 quarters.
  • Ergoteles's BridgeBio Pharma position peaked at $5M in Q3 2021.
  • 213 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.